Chronic Allograft Nephropathy

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 414-429

  Vadivel, Nidyanandh ^a   Tullius, Stefan G ^a   Chandraker, Anil ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

allograft failure; allograft loss; Chronic allograft nephropathy; chronic rejection; transplant outcome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIMETABOLITE; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN A; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PREDNISONE; QUINOLONE DERIVATIVE; RAPAMYCIN; RELAXIN; RITUXIMAB; TACROLIMUS;

ALLOGRAFT; ARTICLE; BIOPSY; BODY MASS; CELLULAR IMMUNITY; COMPARATIVE STUDY; CORRELATION ANALYSIS; DEATH; DIALYSIS; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMORAL IMMUNITY; HYALINE DEGENERATION; HYPERTENSION; IMMUNE RESPONSE; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SURVIVAL TIME;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PREVALENCE; TRANSPLANTATION, HOMOLOGOUS; WORLD HEALTH;

EID: 34347235417     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.004     Document Type: Article

References (106)

1. U.S. Renal Data System. USRDS 2004 annual report: atlas of end-stage renal disease in the United States (2004), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Meier-Kriesche H.U., Schold J.D., and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 4 (2004) 1289-1295
3. Cohen D.J., St Martin L., Christensen L.L., Bloom R.D., and Sung R.S. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 6 (2006) 1153-1169
4. Chapman J.R., O'Connell P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015-3026
5. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
6. Solez K., Axelsen R.A., Benediktsson H., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44 (1993) 411
7. Ivanyi B. Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection. Nephrol Dial Transplant 18 (2003) 655-660
8. Solez K., VIncenti F., and Filo R. Histopathological findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 kidney transplant study group. Transplantation 66 (1998) 1736-1740
9. Glassock R.J., Feldman D., Reynolds E.S., Dammin G.J., and Merrill J.P. Human renal isografts: a clinical and pathologic analysis. Medicine 47 (1968) 411-454 (Baltimore)
10. Tullius S.G., and Tilney N.L. Both allo-antigen dependent and independent factors influence chronic allograft rejection. Transplantation 59 (1995) 313-318
11. Sayegh M.H., and Carpenter M.H. Role of indirect allorecognition in allograft rejection. Int Rev Immunol 13 (1996) 221-229
12. Vella J.P., Spadafora-Ferreira M., Murphy B., Alexander S.I., Harmon W., Carpenter C.B., and Sayegh M.H. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 64 (1997) 795-800
13. Ciubotariu R., Liu Z., Colovai A.I., Ho E., Itescu S., Ravalli S., Hardy M.A., Cortesini R., Rose E.A., and Suciu-Foca N. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 101 (1998) 398-405
14. Rothstein D.M., and Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 196 (2003) 85-108
15. Khoury S.J., and Sayegh M.H. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 20 (2004) 529-538
16. Adams A.B., Shirasugi N., Jones T.R., Durham M.M., Strobert E.A., Cowan S., Rees P., Hendrix R., Price K., Kenyon N.S., Hagerty D., Townsend R., Hollenbaugh D., Pearson T.C., and Larsen C.P. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 174 (2005) 542-550
17. Kirk A.D., Harlan D.M., Armstrong N.N., Davis T.A., Dong Y., Gray G.S., Hong X., Thomas D., Fechner Jr. J.H., and Knechtle S.J. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 (1997) 8789-8794
18. Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 55 (2003) 57-66
19. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., Lang P., Grinyo J., Halloran P.F., Solez K., Hagerty D., Levy E., Zhou W., Natarajan K., and Charpentier B. Belatacept Study Group Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
20. Russell P., Chase C., Winn H., et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 152 (1994) 5135-5141
21. Regele H., Bohmig G.A., Habicht A., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries. J Am Soc Nephrol 13 (2002) 2371-2380
22. Mauiyyedi S., Pelle P.D., Saidman S., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12 (2001) 574-582
23. Pelletier R.P., Hennessy P.K., Adams P.W., et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2 (2002) 134-141
24. Tinckam K.J., and Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 1 (2006) 404-414
25. Terasaki P.I., and Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 80 (2005) 1194-1197
26. van Saase J.L., van der Woude F.J., Thorogood J., Hollander A.A., van Es L.A., Weening J.J., van Bockel J.H., and Bruijn J.A. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 59 (1995) 1280-1285
27. Sijpkens Y.W., Doxiadis I.I., De Fijter J.W., Mallat M.J., van Es L.A., De Lange P., Zwinderman A.H., Westendorp R.G., van Kemenade F.J., Bruijn J.A., Claas F.H., and Paul L.C. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 56 (1999) 1920-1927
28. Humar A., Kerr S., Gillingham K.J., and Matas A.J. Features of acute rejection that increase risk for chronic rejection. Transplantation 68 (1999) 1200-1203
29. Humar A., Payne W.D., Sutherland D.E., and Matas A.J. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 69 (2000) 2357-2360
30. Joseph J.T., Kingsmore D.B., Junor B.J., Briggs J.D., Mun Woo Y., Jaques B.C., Hamilton D.N., Jardine A.G., and Jindal R.M. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 15 (2001) 221-227
31. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
32. Matas A.J., Gillingham K.J., Payne W.D., and Najarian J.S. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57 (1994) 857-859
33. Kaplan B. Overcoming barriers to long-term graft survival. Am J Kidney Dis 47 Suppl 2 (2006) S52-S64
34. Hata Y., Cecka J.M., Takemoto S., et al. Effects of changes in the criteria for nationally shared kidney transplants for HLA-matched patients. Transplantation 65 (1998) 208-212
35. Morris P.J., Johnson R.J., Fuggle S.V., et al., HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. Lancet 354 (1999) 1147-1152
36. Opelz G. New immunosuppressions and HLA matching. Transplant Proc 33 (2001) 467-468
37. Pirsch J.D., D'Alessandro A.M., Sollinger H.W., Hoffmann R.M., Roecker E., Voss B.J., Lorentzen D., Knechtle S.J., Reed A., Kalayoglu M., et al. The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients. Transplantation 53 (1992) 55-59
38. Takemoto S., Port F.K., Claas F.H., and Duquesnoy R.J. HLA matching for kidney transplantation. Hum Immunol 65 (2004) 1489-1505
39. Sijpkens Y.W., Doxiadis I.I., and De Fijter J.W. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 10 (1999) 2237-2243
40. Sijpkens Y.W., Doxiadis I.I., Mallat M.J., et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 75 (2003) 204-220
41. Takemoto S.K., Cho Y.W., and Gjertson D.W. Transplant risks. In: Terasaki P.I., and Cecka J.M. (Eds). Clinical transplants 1999 (1999), Tissue Typing Laboratory, Los Angeles 325
42. Goldfarb-Rumyantzev A., Hurdle J.F., Scandling J., et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 20 (2005) 167-175
43. Neylan J.F., Sayegh M.H., Coffman T.M., et al., ASN Transplant Advisory Group, American Society of Nephrology. The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy. J Am Soc Nephrol 10 (1999) 2237-2243
44. Guttmann R.D. Cadaver kidneys: the rules of rationing. Lancet 348 (1996) 456-457
45. Helderman J.H., and Goral S. The allocation of cadaveric kidneys. N Engl J Med 341 (1999) 1468-1469
46. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 (2005) 1570-1576
47. Martin L., Guignier F., Mousson C., et al. Detection of donor specific anti HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 76 (2003) 395-400
48. Beimler J.H., Susal C., and Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 20 Suppl 17 (2006) 7-12
49. Almond P., Matas A., Gillingham K., et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 55 (1993) 752-756
50. Ratcliffe P.J., Dudley C.R., Higgins R.M., et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 348 (1996) 643-648
51. Alijani M.R., Cutler J.A., and DelValle C.J. Single-donor cold storage versus machine perfusion in cadaver kidney preservation. Transplantation 40 (1985) 659-661
52. Halloran P., and Aprile M. A randomized prospective trial of cold storage versus pulsatile perfusion for cadaver kidney preservation. Transplantation 43 (1987) 827-883
53. Polyak M.M., Arrington B.O., Stubenbord W.T., et al. The influence of pulsatile preservation on renal transplantation in the 1990s. Transplantation 69 (2000) 249-258
54. Heeman U., Azuma H., Tullius S., et al. The contribution of reduced functional mass to chronic kidney allograft dysfunction in rats. Transplantation 58 (1994) 1317-1322
55. Mackenzie H.S., Tullius S.G., Heeman U.W., et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 94 (1994) 2148-2152
56. Neugarten J., Srinivas T., Tellis V., Silbiger S., and Greenstein S. The effect of donor gender on renal allograft survival. J Am Soc Nephrol 7 (1996) 318-324
57. Brenner B.M., and Milford E.L. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 21 (1993) 66-72
58. Papadimitriou J.C., Coale R., Farney A., Schweitzer E., Foster C., Campos L., and Bartlett S. Biopsy of the marginal kidney donor: correlation of histology with outcome. Transplant Proc 36 (2004) 742-744
59. Womer K.L., Vella J.P., and Sayegh M.H. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 20 (2000) 126-147
60. Nijboer W.N., Schuurs T.A., van der Hoeven J.A., Leuvenink H.G., van der Heide J.J., van Goor H., and Ploeg R.J. Effects of brain death on stress and inflammatory response in the human donor kidney. Transplant Proc 37 (2005) 367-369
61. Takada M., Nadeau K., Hancock W., et al. Effects of explosive brain death on cytokine activation of peripheral organs in rat. Transplantation 65 (1998) 1533-1542
62. Pratschke J., Wilhelm M.J., Kusaka M., Beato F., Milford E.L., Hancock W.W., and Tilney N.L. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg 232 (2000) 263-271
63. Wilhelm M.J., Pratschke J., Beato F., Taal M., Kusaka M., Hancock W.W., and Tilney N.L. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 102 (2000) 2426
64. Alonso A., Fernandez-Rivera C., Villaverde P., Oliver J., Cillero S., Lorenzo D., and Valdes F. Renal transplantation from non-heart-beating donors: a single-center 10-year experience. Transplant Proc 37 (2005) 3658-3660
65. Tullius S., Heemann U., Hancock W., et al. Long term kidney isografts develop functional and morphological changes that mimic those of chronic allograft rejection. Ann Surg 220 (1994) 432-435
66. Coulson M.T., Jablonski P., Howden B.O., Thomson N.M., and Stein A.N. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 80 (2005) 353-361
67. Chandraker A., Takada M., Nadeau K.C., et al. CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int 52 (1997) 1678-1684
68. Land W., Schneeberger H., Schleibner S., et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 57 (1994) 211-217
69. Gueler F., Gwinner W., Schwarz A., and Haller H. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 66 (2004) 523
70. Kotsch K., Francuski M., Pascher A., et al. Improved long-term graft survival after HO-1 induction in brain dead donors. Am J Transplant 6 (2006) 477-486
71. Opelz G., Wujciak T., and Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53 (1998) 217-222
72. Mange K.C., Cizman B., Joffe M., and Feldman H.L. Arterial hypertension and renal allograft survival. JAMA 283 (2000) 633-638
73. Kasiske B.L., Anjum S., Shah R., et al. Hypertension after kidney transplantation. Am J Kidney Dis 43 (2004) 1071-1081
74. Opelz G., and Döhler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 5 (2005) 2725
75. Mailloux L.U., and Levey A.S. Hypertension in patients with chronic renal disease. Am J Kidney Dis 32 Suppl 3 (1998) S120-S141
76. Lin J., Valeri A.M., Markowitz G.S., et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 73 (2002) 783-788
77. Opelz G., Zeier M., Laux G., et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17 (2006) 3257-3262
78. Wissing K.M., Abramowicz D., Broeders N., et al. Hypercholestrolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 70 (2000) 464-472
79. Aakus S., Dahl K., and Wideroe T.E. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14 (1999) 648-654
80. Mathis A.S., Dave N., Knipp G.T., and Friedman G.S. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61 (2004) 565-587
81. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2 (2002) 807-818
82. Murgia M.G., Jordan S., and Kahan B.D. The side effect profile of sirolimus: a phase I study of quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49 (1996) 209-216
83. Blum C.B. Effects of sirolimus on lipids in renal allograft recipients: an analysis using Framingham risk model. Am J Transplant 2 (2002) 551-559
84. Elloso M.M., Azrolan N., Sehgal S.N., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. Am J Transplant 3 (2003) 562-569
85. National Kidney Foundation. Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations. Am J Kidney Dis 41 Suppl 3 (2003) S11-S91
86. Holdaas H., Fellstrom B., Jardine A.G., et al. Effects of fluvastatin on cardiac events in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 361 (2003) 2024-2031
87. Meier-Kriesche H.U., Arndorfer J.A., and Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 73 (2002) 70-74
88. Gore J.L., Pham P.T., Danovitch G.M., Wilkinson A.H., Rosenthal J.T., Lipshutz G.S., and Singer J.S. Obesity and outcome following renal transplantation. Am J Transplant 6 (2006) 357
89. Hirsch H.H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347 (2002) 488
90. Brennan D.C., Agha I., Bohl D.L., et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5 (2005) 582
91. Binet I., Nickeleit V., Hirsch H.H., et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 67 (1999) 918
92. Trofe J., Roy-Chaudhury P., Gordon J., et al. Early cessation/avoidance regimens are associated with lower incidence of polyomavirus nephropathy. Am J Transplantation 3 (2003) 371
93. Dadhania D., Muthukumar T., Snopkowski C., et al. Epidemiology of BK virus replication in renal allograft recipients and identification of corticosteroid maintenance therapy as an independent risk factor. Am J Transplantation 4 (2004) S198
94. Mengel M., Marwedel M., Radermacher J., et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18 (2003) 1190
95. Hirsch H.H., Brennan D.C., and Drachenberg C.B. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 (2005) 1277-1286
96. Inkinen K., Soots A., Krogerus L., et al. Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats. Transplant Int 18 (2005) 743
97. Weir M.R., Ward M.T., Blahut S.A., et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59 (2001) 1567
98. Dudley C.R.K., et al., MMF "Creeping Creatinine" Study Group. MMF substitution for CsA is an effective and safe treatment of chronic allograft dysfunction; results of a multi-center randomized controlled trial (2002), American Transplant Congress, Washington
99. Flechner S.M., Goldfarb D., Modlin C., et al. Kidney transplantation without calcineurin inhibitor drugs a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74 (2002) 1070
100. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6 (2006) 514-522
101. Mannon R.B. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 6 (2006) 867-875
102. Ling H., Li X., Jha S., Wang W., Karetskaya L., Pratt B., and Ledbetter S. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 14 (2003) 377-388
103. Khanna A.K., Plummer M.S., Hilton G., Pieper G.M., and Ledbetter S. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival. Circulation 110 (2004) 3822-3829
104. Dong V.M., Yuan X., Coito A.J., Waaga A.M., Sayegh M.H., and Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 73 (2002) 1310-1317
105. Wekerle T., Kurtz J., Ito H., Ronquillo J.V., Dong V., Zhao G., Shaffer J., Sayegh M.H., and Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6 (2000) 464-469
106. Kosuge H., Suzuki J., Gotoh R., Koga N., Ito H., Isobe M., Inobe M., and Uede T. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75 (2003) 1374-1379